Daniel G. Aaron, Michael S. Sinha & I. Glenn Cohen, The FDA’s Leucovorin Approval—A Departure From Evidentiary Standards, JAMA (2025).
Abstract: This Viewpoint explores the US Food and Drug Administration’s plan to approve leucovorin for patients with autism and the potential implications for evidentiary standards.